Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? The pharmaceutical giant expects sales to decline this year, potentially by double-digit percentages.
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.
Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season? Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
What Drove US Indices Down Today? Investors dumped technology stocks as they move to safer assets like Gold and Silver that rose today.
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli
Is Novo Nordisk Stock a Bargain Right Now? Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.
Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk.
2 Beaten-Down Growth Stocks Ready to Bounce Back Both companies are trading at attractive valuations today.
1 Biotech Stock Set to Rebound in 2026 The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate.
1 Pharmaceutical Stock Set to Rebound in 2026 Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.
2 Pharmaceutical Stocks Set to Rebound in 2026 There might be massive upside ahead for these drugmakers.
Where Will Eli Lilly Be in 10 Years? Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.
Prediction: This Healthcare Stock Could Soar by 40% in 2026 This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning.
3 Growth Stocks to Invest $1,000 in Right Now It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.
